JP2006514923A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514923A5
JP2006514923A5 JP2004546264A JP2004546264A JP2006514923A5 JP 2006514923 A5 JP2006514923 A5 JP 2006514923A5 JP 2004546264 A JP2004546264 A JP 2004546264A JP 2004546264 A JP2004546264 A JP 2004546264A JP 2006514923 A5 JP2006514923 A5 JP 2006514923A5
Authority
JP
Japan
Prior art keywords
depot preparation
preparation according
injectable depot
ziprasidone
sbecd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2004546264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514923A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/004576 external-priority patent/WO2004037289A2/en
Publication of JP2006514923A publication Critical patent/JP2006514923A/ja
Publication of JP2006514923A5 publication Critical patent/JP2006514923A5/ja
Abandoned legal-status Critical Current

Links

JP2004546264A 2002-10-25 2003-10-13 注射可能な新規なデポ製剤 Abandoned JP2006514923A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42147302P 2002-10-25 2002-10-25
PCT/IB2003/004576 WO2004037289A2 (en) 2002-10-25 2003-10-13 Novel injectable depot formulations

Publications (2)

Publication Number Publication Date
JP2006514923A JP2006514923A (ja) 2006-05-18
JP2006514923A5 true JP2006514923A5 (enExample) 2006-11-24

Family

ID=32176718

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004546264A Abandoned JP2006514923A (ja) 2002-10-25 2003-10-13 注射可能な新規なデポ製剤

Country Status (20)

Country Link
US (1) US20040138237A1 (enExample)
EP (1) EP1575616A2 (enExample)
JP (1) JP2006514923A (enExample)
KR (1) KR20050055781A (enExample)
CN (1) CN1849110A (enExample)
AR (1) AR041722A1 (enExample)
AU (1) AU2003267788A1 (enExample)
BR (1) BR0315568A (enExample)
CA (1) CA2503076A1 (enExample)
MX (1) MXPA05002561A (enExample)
NL (1) NL1024590C2 (enExample)
NO (1) NO20052463L (enExample)
PA (1) PA8586201A1 (enExample)
PE (1) PE20040499A1 (enExample)
PL (1) PL377679A1 (enExample)
RU (1) RU2310450C2 (enExample)
TW (1) TW200423941A (enExample)
UY (1) UY28038A1 (enExample)
WO (1) WO2004037289A2 (enExample)
ZA (1) ZA200501921B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
SI1575569T1 (sl) 2002-12-13 2010-12-31 Durect Corp Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
BRPI0414082A (pt) * 2003-09-02 2006-10-24 Pfizer Prod Inc formas de dosagem de liberação sustentada de ziprasidona
SI2767292T1 (sl) 2004-09-17 2017-01-31 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
EP1874267A1 (en) * 2005-04-13 2008-01-09 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
KR20070119678A (ko) * 2005-04-13 2007-12-20 화이자 프로덕츠 인코포레이티드 지속 방출되는 나노입자 조성물을 제공하기 위한주사가능한 저장소 제제 및 방법
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
EP1901722A4 (en) * 2005-06-20 2011-06-15 Elan Pharma Int Ltd NANOTEHOUS COMPOSITIONS WITH CONTROLLED RELEASE FROM ARYL-HETEROCYCLIC COMPOUNDS
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
KR100908517B1 (ko) * 2006-07-04 2009-07-20 (주)아모레퍼시픽 호흡기계 약제 전달을 위한 서방형 다공성 미세입자 및 그제조 방법
EP2117521B1 (en) 2006-11-03 2012-06-27 Durect Corporation Transdermal delivery systems comprising bupivacaine
CA2687979C (en) 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
EP2067471B1 (en) * 2007-12-06 2018-02-14 Durect Corporation Oral pharmaceutical dosage forms
JP5643195B2 (ja) * 2008-06-16 2014-12-17 デビオファーム インターナショナル ソシエテ アノニム 濃縮オキサリプラチン溶液及びその調製方法
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CN104688686A (zh) * 2015-02-10 2015-06-10 万全万特制药江苏有限公司 一种含有齐拉西酮及其盐的脂肪乳注射剂
JP7258561B2 (ja) 2016-07-06 2023-04-17 オリエント ファーマ シーオー.,エルティーディー. 薬物組成物、バリヤー層及び薬物層を有している経口投与形態
WO2018015915A1 (en) * 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
AU2019250128A1 (en) 2018-10-15 2020-04-30 Avent Inc. Compositions, systems, kits, and methods for neural ablation
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
KR20230145053A (ko) 2021-01-12 2023-10-17 듀렉트 코퍼레이션 지속 방출 약물 전달 시스템 및 관련 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029782A (en) * 1975-04-28 1977-06-14 Eli Lilly And Company Cefazolin suspension for parenteral administration
US4512986A (en) * 1983-07-26 1985-04-23 Research Triangle Institute Progrestationally active steroids
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
AU739469B2 (en) * 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
CA2328197C (en) * 1998-04-14 2007-11-20 The General Hospital Corporation Methods for treating neuropsychiatric disorders
EE04704B1 (et) * 1999-05-27 2006-10-16 Pfizer Products Inc. Ziprasidooni suspensioon
US6753011B2 (en) * 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
CA2441744C (en) * 2001-03-20 2011-07-12 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers

Similar Documents

Publication Publication Date Title
JP2006514923A5 (enExample)
JP2006514923A (ja) 注射可能な新規なデポ製剤
CN100374112C (zh) 罗替戈汀鼻内组合物
EP1312356B1 (en) Aqueous suspension preparations
JP2005514349A5 (enExample)
US5773608A (en) Process for preparing stabilized chitin derivative compounds
US20090047330A1 (en) Oral fast dissolving films for erectile dysfunction bioactive agents
JP2007500244A5 (enExample)
RU2005112202A (ru) Депо-препараты арилгетероциклических активных веществ в виде суспензии
JP2006528990A5 (enExample)
CA2717605A1 (en) Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
IT1243390B (it) Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
JP2003512341A5 (enExample)
TR200101088T2 (tr) Sürekli salınımlı farmasötik kompozisyon ve farmasötik olarak aktif ajanın salınma metodu
EP1968638B1 (en) Controlled release gels
US20100267817A1 (en) Lyophilized pharmaceutical composition with improved reconstitution time containing taxane derivatives and method of manufacturing the same
JPH1072376A (ja) ヒアルロン酸含有点眼水溶液
CN100444828C (zh) 一种生物降解聚合物药物微球的制备方法
KR20220104114A (ko) 안과용 조성물
JPH092977A (ja) 経口投与用医薬組成物
US20040142039A1 (en) Solid and semi-solid polymeric ionic conjugates
JP2004149468A (ja) 皮膚外用剤組成物
JP2006052172A5 (enExample)
JP2001125052A (ja) コンタクトレンズ装着液
JPH1192368A (ja) ベンゾピラン誘導体を主成分とする水性液剤